Incomplete GRAS Requests Put Credibility At Risk – Expert
This article was originally published in The Tan Sheet
Executive Summary
Firms risk losing credibility with FDA if they omit unfavorable data and include only positive information with generally recognized as safe submissions, says consultant Michael Falk